DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Multifocal atrial tachycardia, druginduced,
821t
Multigenic trait, 152f
Multiple-dose activated charcoal, 85
Multiple myeloma (MM), 1741–1742,
1743, 1755
drugs for, 1668t–1670t
Multiple Risk Factor Intervention Trial
(MRFIT), 891
Multiple sclerosis, immunotherapy for,
1025–1027
Multivitamins, in pregnancy, 1846
Mupirocin, 1544
antimicrobial activity, 1817
formulations, 1817
mechanism of action of, 1817
for skin infections, 1817
MUROCOLL-2, 1788
Muscarine, 219, 222f, 223–225
pharmacological properties of, 223t
Muscarinic agonists, 222–225
acetylcholine and, 219
receptors subtypes and, 220
Muscarinic antagonists, 225–235
for asthma, 1044–1046
in children, 235
contraindications, 234
in infants, 235
paradoxical effects of, 225–226
for Parkinson, 618–619
receptor subtypes and, 220
Muscarinic cholinergic receptors
antidepressant potencies at, 410t
antipsychotics and, 427t
Muscarinic receptors, 189
acetylcholine and, 219–222
allosteric binding sites in, 220
in cognition, 223–224
locations of, 219
neuromuscular blocking agents and,
262
properties of, 219–220
salivary secretion and, 222
subtypes of, 190–194, 192t–193t,
219–220
Muscle
acetylcholinesterase and, 188
adrenocorticosteroids and, 1221
alpha adrenergic receptors in, 203t
amphetamines and, 297
beta adrenergic receptors in, 204t
epinephrine and, 284–285
ethanol and, 636–637
halothane and, 547
isoflurane and, 548
Muscle (Cont.):
meperidine and, 506
neuromuscular blocking agents and,
258–261
relaxation, with neuromuscular
blocking agents, 265–266
Muscle-type nicotinic receptors, 190,
191t
MUSE (alprostandil), 952
Mushroom poisoning, 225
MUSTARGEN (mechlorethamine HCl),
1821
MUTAMYCIN (mitomycin), 1789
Myalgias, statins and, 897
Myasthenia gravis
anticholinesterase agents for, 234,
251–252
diagnosis of, 251
ocular symptoms, 1788
treatment of, 251–252
Myasthenic syndrome, 102t
Mycobacterial infections, 1549
drugs for, 1549–1564
Mycobacterium avium complex
disseminated, 1566
principles of therapy, 1565–1566
Mycophenolate mofetil, 1014
in dermatology, 1822–1823
mechanism of action of, 1820t
Mycophenolic acid, 1822–1823
pharmacokinetics of, 1867t
Mycosis fungoides, drugs for,
1668t–1670t
MYDRIACYL (tropicamide), 1788
Mydriasis, 228, 233, 1776
autonomic agents for, 1785t, 1786t
epinephrine and, 286
Myelodysplastic syndrome (MDS),
1741–1742
Myeloid growth factors, 1070t,
1073–1076
Myenteric plexus, 174, 175
MYFORTIC (mycophenolate sodium),
1822–1823
MYKROX (metolazone), 688t
MYLANTA EXTRA STRENGTH, 1316t
MYLOTARG (gemtuzumab ozogamicin),
1745
Myocardial infarction
acute (AMI)
beta-adrenergic antagonists for,
768
nitrates for, 760–761
treatment of, 767
acute (AMI), ACE inhibitors in, 735
Myocardial infarction (Cont.):
beta-adrenergic receptor antagonists
in, 317
dyslipidemia treatment after, 890
non-ST-segment elevation, nitrates
for, 760
Myocardial ischemia, 751–772. See
also Angina pectoris
anti-integrin agents for, 771
antiplatelet agents for, 771
antithrombotic agents for, 771
beta-adrenergic antagonists for,
767–768 (See also Betaadrenergic
receptor
antagonists)
calcium channel antagonists for,
761–767 (See also Calcium
channel antagonists)
absorption, fate, and excretion of,
765
chemistry of, 761
history of, 761
mechanism of action of,
761–763
pharmacological properties of,
763–766
therapeutic uses of, 766–767
toxicity and untoward responses
to, 765–766
endovascular stents for, drugeluting,
772
ischemic burden in, 751
mechanopharmacological therapy
for, 772
organic nitrates for, 753–761
adverse effects and side effects of,
758–759
chemistry of, 753
dosage and administration of,
754t
history of, 753
interaction with
phosphodiesterase inhibitors,
758–759
mechanism of action of,
753–754
nomenclature for, 754t
pharmacological properties of,
753–757
structures, 754t
therapeutic uses of, 759–761
tolerance, 757–758
toxicity of, 758–759
silent, 751–752
symptoms of, 751–752
2049
INDEX